Agency Information Collection Activities; Proposed Collection; Comment Request; Record Retention Requirements for the Soy Protein and Risk of Coronary Heart Disease Health Claim, 49295-49296 [05-16658]
Download as PDF
Federal Register / Vol. 70, No. 162 / Tuesday, August 23, 2005 / Notices
49295
TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN1—Continued
No. of
Respondents
21 CFR Section
Annual Frequency
per Response
Total Annual
Responses
Hours per
Response
Total
4,000
1There
are no capital costs or operating and maintenance costs associated with this collection of information.
In the Federal Register of May 3, 2005
(70 FR 22887), FDA published a 60-day
notice requesting public comment on
the information collection provisions.
No comments were received.
Dated: August 17, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 05–16656 Filed 8–22–05; 8:45 am]
BILLING CODE 4160–01–S
Dated: August 17, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 05–16657 Filed 8–22–05; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2005N–0317]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Record Retention
Requirements for the Soy Protein and
Risk of Coronary Heart Disease Health
Claim
Food and Drug Administration
[Docket No. 2005N–0029]
Agency Information Collection
Activities; Announcement of Office of
Management and Budget Approval;
Infant Formula Recall Regulations
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Total Hours
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a collection of information entitled
‘‘Infant Formula Recall Regulations’’ has
been approved by the Office of
Management and Budget (OMB) under
the Paperwork Reduction Act of 1995.
FOR FURTHER INFORMATION CONTACT:
Peggy Robbins, Office of Management
Programs (HFA–250), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–827–1223.
In the
Federal Register of February 1, 2005 (70
FR 5188), the agency announced that
the proposed information collection had
been submitted to OMB for review and
clearance under 44 U.S.C. 3507. An
agency may not conduct or sponsor, and
a person is not required to respond to,
a collection of information unless it
displays a currently valid OMB control
number. OMB has now approved the
information collection and has assigned
OMB control number 0910–0188. The
approval expires on July 31, 2008. A
copy of the supporting statement for this
information collection is available on
the Internet at https://www.fda.gov/
ohrms/dockets.
SUPPLEMENTARY INFORMATION:
VerDate Aug<18>2005
15:03 Aug 22, 2005
Jkt 205001
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing an
opportunity for public comment on the
proposed collection of certain
information by the agency. Under the
Paperwork Reduction Act of 1995 (the
PRA), Federal agencies are required to
publish notice in the Federal Register
concerning each proposed collection of
information, including each proposed
extension of an existing collection of
information, and to allow 60 days for
public comment in response to the
notice. This notice solicits comments on
the record retention requirement of the
soy protein/coronary heart disease
health claim.
DATES: Submit written or electronic
comments on the collection of
information by October 24, 2005.
ADDRESSES: Submit electronic
comments on the collection of
information to: https://www.fda.gov/
dockets/ecomments. Submit written
comments on the collection of
information to the Division of Dockets
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. All
comments should be identified with the
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT:
Peggy Robbins, Office of Management
Programs (HFA–250), Food and Drug
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–827–1223.
SUPPLEMENTARY INFORMATION: Under the
PRA (44 U.S.C. 3501–3520), Federal
agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
Record Retention Requirements for the
Soy Protein and Risk of Coronary Heart
Disease Health Claim—21 CFR
101.82(c)(2)(ii)(B) (OMB Control
Number 0910–0428)—Extension
Section 403(r)(3)(A)(i) of the Federal
Food, Drug, and Cosmetic Act (21 U.S.C.
343(r)(3)(A)(i)) provides for the use of
food label statements characterizing a
relationship of any nutrient of the type
required to be in the label or labeling of
the food to a disease or a health related
condition only where that statement
E:\FR\FM\23AUN1.SGM
23AUN1
49296
Federal Register / Vol. 70, No. 162 / Tuesday, August 23, 2005 / Notices
meets the requirements of the
regulations promulgated by the
Secretary to authorize the use of such a
health claim. Section 101.82 (21 CFR
101.82) of FDA’s regulations authorizes
a health claim for food labels about soy
protein and the risk of coronary heart
disease. To bear the soy protein/
coronary heart disease health claim,
foods must contain at least 6.25 grams
of soy protein per reference amount
customarily consumed. Analytical
methods for measuring total protein can
be used to quantify the amount of soy
protein in foods that contain soy as the
sole source of protein. However, at the
present time there is no validated
analytical methodology available to
quantify the amount of soy protein in
foods that contain other sources of
protein. For these latter foods, FDA
must rely on information known only to
the manufacturer to assess compliance
with the requirement that the food
contain the qualifying amount of soy
protein. Thus, FDA requires
manufacturers to have and keep records
to substantiate the amount of soy
protein in a food that bears the health
claim and contains sources of protein
other than soy, and to make such
records available to appropriate
regulatory officials upon written
request. The information collected
includes nutrient data bases or analyses,
recipes or formulations, purchase orders
for ingredients, or any other information
that reasonably substantiates the ratio of
soy protein to total protein.
FDA estimates the burden of this
collection of information as follows:
TABLE 1.—ESTIMATED ANNUAL RECORDKEEPING BURDEN1
21 CFR Section
No. of Recordkeepers
101.82(c)(2)(ii)(B)
1There
Annual Frequency per
Recordkeeping
25
1
Hours per
Record
25
Total Hours
1
25
are no capital costs or operating and maintenance costs associated with this collection of information.
Based upon its experience with the
use of health claims, FDA estimates that
only about 25 firms would be likely to
market products bearing a soy protein/
coronary heart disease health claim and
that only, perhaps, one of each firm’s
products might contain nonsoy sources
of protein along with soy protein. The
records required to be retained by
§ 101.82(c)(2)(ii)(B) are the records, e.g.,
the formulation or recipe, that a
manufacturer has and maintains as a
normal course of its doing business.
Thus, the burden to the food
manufacturer is that involved in
assembling and providing the records to
appropriate regulatory officials for
review or copying.
Dated: August 17, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 05–16658 Filed 8–22–05; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2004N–0469]
Agency Information Collection
Activities; Announcement of Office of
Management and Budget Approval;
Adverse Experience Reporting for
Licensed Biological Products; and
General Records
AGENCY:
‘‘Adverse Experience Reporting for
Licensed Biological Products; and
General Records’’ has been approved by
the Office of Management and Budget
(OMB) under the Paperwork Reduction
Act of 1995.
FOR FURTHER INFORMATION CONTACT:
Jonna Capezzuto, Office of Management
Programs (HFA–250), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–827–4659.
In the
Federal Register of April 20, 2005 (70
FR 20571), the agency announced that
the proposed information collection had
been submitted to OMB for review and
clearance under 44 U.S.C. 3507. An
agency may not conduct or sponsor, and
a person is not required to respond to,
a collection of information unless it
displays a currently valid OMB control
number. OMB has now approved the
information collection and has assigned
OMB control number 0910–0308. The
approval expires on July 31, 2008. A
copy of the supporting statement for this
information collection is available on
the Internet at https://www.fda.gov/
ohrms/dockets.
SUPPLEMENTARY INFORMATION:
Dated: August 17, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 05–16659 Filed 8–22–05; 8:45 am]
BILLING CODE 4160–01–S
Food and Drug Administration,
HHS.
ACTION:
Total Annual
Records
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a collection of information entitled
VerDate Aug<18>2005
15:03 Aug 22, 2005
Jkt 205001
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2005D–0310]
Draft Guidance for Industry on Gene
Therapy Clinical Trials—Observing
Participants for Delayed Adverse
Events; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
availability of a draft document entitled
‘‘Guidance for Industry: Gene Therapy
Clinical Trials—Observing Participants
for Delayed Adverse Events,’’ dated
August 2005. The draft guidance
provides sponsors of gene therapy
studies with recommendations
regarding collection of data on delayed
adverse events in participants who have
been exposed to gene therapy products.
When finalized, this guidance will
supplement the recommendations in the
‘‘Guidance for Industry: Supplemental
Guidance on Testing for Replication
Competent Retrovirus in Retroviral
Vector Based Gene Therapy Products
and During Follow-up of Patients in
Clinical Trials Using Retroviral Vectors’’
(Retroviral Vector guidance), dated
October 2000, for study participant
long-term followup. However, the
recommendations in the Retroviral
Vector guidance regarding the length of
followup will be superseded by this
Gene Therapy Clinical Trials guidance.
DATES: Submit written or electronic
comments on the draft guidance by
November 21, 2005, to ensure their
E:\FR\FM\23AUN1.SGM
23AUN1
Agencies
[Federal Register Volume 70, Number 162 (Tuesday, August 23, 2005)]
[Notices]
[Pages 49295-49296]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-16658]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 2005N-0317]
Agency Information Collection Activities; Proposed Collection;
Comment Request; Record Retention Requirements for the Soy Protein and
Risk of Coronary Heart Disease Health Claim
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing an
opportunity for public comment on the proposed collection of certain
information by the agency. Under the Paperwork Reduction Act of 1995
(the PRA), Federal agencies are required to publish notice in the
Federal Register concerning each proposed collection of information,
including each proposed extension of an existing collection of
information, and to allow 60 days for public comment in response to the
notice. This notice solicits comments on the record retention
requirement of the soy protein/coronary heart disease health claim.
DATES: Submit written or electronic comments on the collection of
information by October 24, 2005.
ADDRESSES: Submit electronic comments on the collection of information
to: https://www.fda.gov/dockets/ecomments. Submit written comments on
the collection of information to the Division of Dockets Management
(HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061,
Rockville, MD 20852. All comments should be identified with the docket
number found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Peggy Robbins, Office of Management
Programs (HFA-250), Food and Drug Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301-827-1223.
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information, including
each proposed extension of an existing collection of information,
before submitting the collection to OMB for approval. To comply with
this requirement, FDA is publishing notice of the proposed collection
of information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Record Retention Requirements for the Soy Protein and Risk of Coronary
Heart Disease Health Claim--21 CFR 101.82(c)(2)(ii)(B) (OMB Control
Number 0910-0428)--Extension
Section 403(r)(3)(A)(i) of the Federal Food, Drug, and Cosmetic Act
(21 U.S.C. 343(r)(3)(A)(i)) provides for the use of food label
statements characterizing a relationship of any nutrient of the type
required to be in the label or labeling of the food to a disease or a
health related condition only where that statement
[[Page 49296]]
meets the requirements of the regulations promulgated by the Secretary
to authorize the use of such a health claim. Section 101.82 (21 CFR
101.82) of FDA's regulations authorizes a health claim for food labels
about soy protein and the risk of coronary heart disease. To bear the
soy protein/coronary heart disease health claim, foods must contain at
least 6.25 grams of soy protein per reference amount customarily
consumed. Analytical methods for measuring total protein can be used to
quantify the amount of soy protein in foods that contain soy as the
sole source of protein. However, at the present time there is no
validated analytical methodology available to quantify the amount of
soy protein in foods that contain other sources of protein. For these
latter foods, FDA must rely on information known only to the
manufacturer to assess compliance with the requirement that the food
contain the qualifying amount of soy protein. Thus, FDA requires
manufacturers to have and keep records to substantiate the amount of
soy protein in a food that bears the health claim and contains sources
of protein other than soy, and to make such records available to
appropriate regulatory officials upon written request. The information
collected includes nutrient data bases or analyses, recipes or
formulations, purchase orders for ingredients, or any other information
that reasonably substantiates the ratio of soy protein to total
protein.
FDA estimates the burden of this collection of information as
follows:
Table 1.--Estimated Annual Recordkeeping Burden\1\
----------------------------------------------------------------------------------------------------------------
Annual Frequency per Total Annual Hours per
21 CFR Section No. of Recordkeepers Recordkeeping Records Record Total Hours
----------------------------------------------------------------------------------------------------------------
101.82(c)(2)(ii)(B 25 1 25 1 25
)
----------------------------------------------------------------------------------------------------------------
\1\There are no capital costs or operating and maintenance costs associated with this collection of information.
Based upon its experience with the use of health claims, FDA
estimates that only about 25 firms would be likely to market products
bearing a soy protein/coronary heart disease health claim and that
only, perhaps, one of each firm's products might contain nonsoy sources
of protein along with soy protein. The records required to be retained
by Sec. 101.82(c)(2)(ii)(B) are the records, e.g., the formulation or
recipe, that a manufacturer has and maintains as a normal course of its
doing business. Thus, the burden to the food manufacturer is that
involved in assembling and providing the records to appropriate
regulatory officials for review or copying.
Dated: August 17, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 05-16658 Filed 8-22-05; 8:45 am]
BILLING CODE 4160-01-S